Division of Infectious Diseases

Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have received renewal of a major federal grant to continue their collaboration to test and develop new treatments and vaccines against HIV/AIDS — and now COVID-19.

Health care workers, who have been disproportionately affected by the COVID-19 pandemic, will be the first tier of Vanderbilt University Medical Center employees to receive vaccine to prevent SARS-CoV-2 infection.

Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.

Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.

COVID-19 spreads faster and more widely throughout U.S. households than previously reported, according to new preliminary research from a multicenter study led by Vanderbilt University Medical Center researchers and published in, a weekly report from the Centers for Disease Control and Prevention (CDC).

A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).

Studies using large DNA biobanks revealed genetic variants associated with penicillin allergy, the most common type of drug-induced allergic reaction.